• Mon news: Novartis in $745M radiopharma pact. Novo launches Wegovy in China. COVID-era telehealth prescribing extended. Hims & Hers GLP-1 tracker. Promising Gilead liver disease trial. See more on our front page

Ok...so let's say you avoid the upcoming carnage and end up staying....

Lets say you were annointed an S3 position because of an account that will fall apart after Singulair goes off patent. Management does not want to look like a bunch of idiots because they've picked someone who has never earned a title with Merck! Most of those in the last 6-7 years were handpicked asskissers anyway! Now you're stuck with getting rid of competent tenured reps at a time when you may actually need selling skills...new products and new Sr. leadership who must be sold or believe in sales rather than activity! Sounds like a conundrum...maybe a time to get rid of some dud SRD's and DM's...company is at a crossroads...where do it go!
 




Lets say you were annointed an S3 position because of an account that will fall apart after Singulair goes off patent. Management does not want to look like a bunch of idiots because they've picked someone who has never earned a title with Merck! Most of those in the last 6-7 years were handpicked asskissers anyway! Now you're stuck with getting rid of competent tenured reps at a time when you may actually need selling skills...new products and new Sr. leadership who must be sold or believe in sales rather than activity! Sounds like a conundrum...maybe a time to get rid of some dud SRD's and DM's...company is at a crossroads...where do it go!

Disagree... think most of these changes are do to lousy access. Certain regional being closed out of offices. Once easy to see docs are now in groups with highly restrictive policies. They've gone to either no see or more liberal once a month or once a quarter see....what do you expect? Will those gifted S3 get anywhere? Maybe in some offices, but maybe not in even more offices. If this trend hasn't hit your area, just wait, it will....